Debt-free Balance SheetZero reported debt materially reduces near-term solvency risk and interest burden, giving management flexibility to pursue R&D or financing choices. Over 2-6 months this preserves optionality and lowers bankruptcy risk despite operating losses.

Lean Operating StructureA very small headcount implies a lean cost base and lower fixed operating overhead, which can extend runway and allow targeted R&D spending. Sustained low personnel costs help stabilize cash burn dynamics versus larger peers.

Signs Of FCF Improvement (2024)An improvement in free cash flow in 2024 indicates management achieved some cost or working-capital gains. If maintained, this trend can form a durable foundation for eventual cash-flow stabilization and reduce near-term funding needs.

Bears Say

Persistent Operating LossesConsistent negative gross margins and large annual net losses reflect structural unprofitability of core activities. Over months this undermines ability to self-fund R&D or commercialization and necessitates external capital absent a business-model inflection.

Severe Revenue ContractionA ~95% year-over-year revenue collapse shows revenue generation is not resilient and likely dependent on episodic events. This weak top-line base increases execution risk and makes medium-term recovery and scale-up more uncertain.

Structural Cash BurnPersistently negative operating cash flow, worsening to ~-¥1.39B in 2025, indicates the company cannot generate internal funding for operations. This creates a structural dependency on external financing and raises dilution and execution risk over the medium term.

4881 FAQ

What was FunPep Company Limited’s price range in the past 12 months?

FunPep Company Limited lowest stock price was ¥75.00 and its highest was ¥162.00 in the past 12 months.

What is FunPep Company Limited’s market cap?

FunPep Company Limited’s market cap is ¥3.65B.

When is FunPep Company Limited’s upcoming earnings report date?

FunPep Company Limited’s upcoming earnings report date is May 18, 2026 which is in 88 days.

How were FunPep Company Limited’s earnings last quarter?

FunPep Company Limited released its earnings results on Feb 12, 2026. The company reported -¥17.06 earnings per share for the quarter, missing the consensus estimate of N/A by -¥17.06.

Is FunPep Company Limited overvalued?

According to Wall Street analysts FunPep Company Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FunPep Company Limited pay dividends?

FunPep Company Limited does not currently pay dividends.

What is FunPep Company Limited’s EPS estimate?

FunPep Company Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FunPep Company Limited have?

FunPep Company Limited has 40,563,800 shares outstanding.

What happened to FunPep Company Limited’s price movement after its last earnings report?

FunPep Company Limited reported an EPS of -¥17.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.97%.

Which hedge fund is a major shareholder of FunPep Company Limited?

Currently, no hedge funds are holding shares in JP:4881

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FunPep Company Limited

FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis. FunPep Company Limited was incorporated in 2013 and is based in Tokyo, Japan.